Cargando…

Effects of Helicobacter pylori on Levodopa Pharmacokinetics

BACKGROUND: Infection with Helicobacter pylori seems overrepresented in Parkinson’s disease. Clinical observations suggest a suboptimal treatment effect of levodopa in Helicobacter positive patients. OBJECTIVE: Describe and explain the connection between a Helicobacter pylori infection of the upper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyholm, Dag, Hellström, Per M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990449/ https://www.ncbi.nlm.nih.gov/pubmed/33164946 http://dx.doi.org/10.3233/JPD-202298

Ejemplares similares

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
por: Aquilonius, Sten-Magnus, et al.
Publicado: (2017)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
por: Senek, M., et al.
Publicado: (2020)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
por: Senek, Marina, et al.
Publicado: (2017)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Eradication of Helicobacter pylori Infection Improves Levodopa Action, Clinical Symptoms and Quality of Life in Patients with Parkinson's Disease
por: Hashim, Hasriza, et al.
Publicado: (2014)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

An updated calculator for determining levodopa-equivalent dose
por: Nyholm, D., et al.
Publicado: (2021)

The effect of Helicobacter pylori on asthma and allergy
por: Amedei, Amedeo, et al.
Publicado: (2010)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
por: Grétarsdóttir, Helga María, et al.
Publicado: (2021)

Helicobacter pylori and gastric acid: an intimate and reciprocal relationship
por: Waldum, Helge L., et al.
Publicado: (2016)

Epigenetics and Helicobacter pylori
por: Capparelli, Rosanna, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Management of Helicobacter pylori
por: Shiota, Seiji, et al.
Publicado: (2010)

Effectiveness of Citrus Fruits on Helicobacter pylori
por: Mandalari, Giuseppina, et al.
Publicado: (2017)

Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration
por: Nedorubov, Andrey Anatolievich, et al.
Publicado: (2019)

Current Helicobacter pylori Diagnostics
por: Bordin, Dmitry S., et al.
Publicado: (2021)

Helicobacter pylori infection in children
por: Aguilera Matos, Idalmis, et al.
Publicado: (2020)

Helicobacter pylori Infections in Children
por: Nguyen, Julie, et al.
Publicado: (2023)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Helicobacter pylori outer membrane vesicles involvement in the infection development and Helicobacter pylori-related diseases
por: Chmiela, Magdalena, et al.
Publicado: (2018)

Helicobacter Pylori Infection in Children
por: Rajindrajith, Shaman, et al.
Publicado: (2009)

Helicobacter pylori: Eradication or Preservation
por: Sachs, George, et al.
Publicado: (2012)

Diet and Helicobacter pylori infection
por: Hołubiuk, Łukasz, et al.
Publicado: (2016)

Management of Helicobacter pylori infection
por: Aumpan, Natsuda, et al.
Publicado: (2022)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

Helicobacter Pylori
por: Aguilar Lasserre, Rubén
Publicado: (1998)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
por: Adamiak-Giera, Urszula, et al.
Publicado: (2021)

Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience
por: Thomas, Ilias, et al.
Publicado: (2019)

The antibacterial effect of fatty acids on Helicobacter pylori infection
por: Jung, Sung Woo, et al.
Publicado: (2016)

Antimicrobial Effects of Lactoferrin against Helicobacter pylori Infection
por: Imoto, Ichiro, et al.
Publicado: (2023)

Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring
por: Contin, Manuela, et al.
Publicado: (2022)

Helicobacter pylori: Commensal, symbiont or pathogen?
por: Reshetnyak, Vasiliy Ivanovich, et al.
Publicado: (2021)

Helicobacter pylori Treatment Strategies in Singapore
por: Ang, Tiing Leong, et al.
Publicado: (2021)

Clinical Relevance of Helicobacter pylori Infection
por: Mladenova, Irena
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5nk3sngvogdq761cr8i72609ku